Market reaction reflects interest in Abivax HIV breakthrough

3 May 2017

Shares in French biotech Abivax (Euronext Paris: ABVX) were up by more than 150% at times on Tuesday as markets reacted to news of a potentially important HIV breakthrough, albeit with mid-stage results.

The company announced that its lead candidate ABX464 demonstrated the first reduction in HIV reservoirs ever observed in chronically infected patients as measured by total HIV DNA detected in peripheral blood mononuclear cells (PBMCs).

"We embrace the deep responsibility we have towards all HIV patients and the HIV community in driving this unique compound forward"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK